Divestment of South African Business Unit to Litha

Aspen is pleased to announce that Pharmacare Limited (“Pharmacare”), a wholly owned subsidiary of Aspen Holdings and the Group’s primary South African trading company, has concluded a set of agreements with Litha Pharma (Pty) Ltd (“Litha”) (a wholly owned South African subsidiary of Endo International Plc) in terms which Pharmacare will divest a business unit which forms part of its pharmaceutical division to Litha for a consideration of approximately R1.6 billion (“the Transaction”).

The business unit concerned has a product portfolio comprising injectables and established brands. This portfolio recorded revenue of R362 million and a direct contribution to profit before tax of R136 million for the year ended 30 June 2014.

The Transaction forms part of Aspen’s communicated strategic intent to focus attention in areas where most value can be added and to lessen complexity.

The Transaction is conditional upon, inter alia, the approval of the South African Competition Authorities.

Durban

11 May 2015

Sponsor:

Investec Bank Limited

我们的使命

更多详情

致力于提高患者的生命健康和质量

我们的愿景

更多详情

作为一个负责任的企业公民,在全球提高优质和患者可及的药物,传递我们的价值。

我们的价值观

更多详情

我们的价值观是爱施健存立和发展的基石。集团上下以此为指引,为实现集团目标而共同奋斗。

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.